Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine develops investigational treatments for serious hematologic diseases by targeting red blood cell biology, including heme biosynthesis and iron homeostasis. News about IRON centers on its clinical-stage pipeline, including bitopertin for erythropoietic protoporphyria, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders.
Recurring updates include clinical trial progress, medical-meeting presentations, FDA communications, quarterly financial results, business updates, investor-conference participation, and leadership or organizational changes tied to the company’s development and commercialization planning.
Disc Medicine, a clinical-stage biopharmaceutical company, will present data from its hematology portfolio at the European Hematology Association (EHA) 2024 Congress in Madrid from June 13-16, 2024.
Key presentations include:
- AURORA trial: Phase 2, double-blind study of Bitopertin in erythropoietic protoporphyria.
- BEACON trial: Phase 2, open-label study of Bitopertin in erythropoietic protoporphyria.
- Phase 1b study: DISC-0974 in myelofibrosis patients with anemia, featuring a larger dataset and longer follow-up.
- Phase 1 study: Initial safety and pharmacodynamic data on DISC-3405 in healthy volunteers.
Management will discuss the data on June 14th at 8:00 am ET. Full abstracts are available on the EHA conference website.
Disc Medicine, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright BioConnect Investor Conference on May 20th. The company focuses on developing treatments for hematologic diseases. The event will feature a fireside chat available via live webcast and archived replay on the company's website.
Disc Medicine, Inc. (NASDAQ:IRON) reported its financial results for Q1 2024, ending with $343M in cash. The AURORA trial showed positive results for bitopertin in EPP patients, reducing toxic PPIX levels and improving quality of life. The company plans to present more data from BEACON and AURORA in Q2 2024, with positive regulatory interactions expected in the second half of the year. DISC-0974 and DISC-3405 also show promising results with upcoming data releases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.